Wendy Mcdermott
Ufficiale delle Risorse Umane presso LEXICON PHARMACEUTICALS, INC.
Patrimonio netto: 88 526 $ in data 30/06/2024
Posizioni attive di Wendy Mcdermott
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Ufficiale delle Risorse Umane | 01/01/2022 | - |
Storia della carriera di Wendy Mcdermott
Precedenti posizioni note di Wendy Mcdermott
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Sanofi Corp. | Ufficiale delle Risorse Umane | 01/01/2017 | 01/01/2019 |
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Ufficiale delle Risorse Umane | 01/01/2019 | - |
Formazione di Wendy Mcdermott
| State University of New York College at Plattsburgh | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Human Resources Officer | 3 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
| Sanofi Corp. |
- Borsa valori
- Insiders
- Wendy Mcdermott
- Esperienza